carbapenems has been researched along with cefiderocol in 56 studies
| Studies (carbapenems) | Trials (carbapenems) | Recent Studies (post-2010) (carbapenems) | Studies (cefiderocol) | Trials (cefiderocol) | Recent Studies (post-2010) (cefiderocol) |
|---|---|---|---|---|---|
| 7,355 | 147 | 5,277 | 250 | 14 | 249 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 7 (12.50) | 24.3611 |
| 2020's | 49 (87.50) | 2.80 |
| Authors | Studies |
|---|---|
| Ito, A; Ito-Horiyama, T; Kohira, N; Nakamura, R; Rittenhouse, S; Sato, T; Tsuji, M; West, J; Yamano, Y | 1 |
| Falagas, ME; Legakis, NJ; Skalidis, T; Vardakas, KZ | 1 |
| Ishibashi, N; Ito, A; Ito-Horiyama, T; Nishikawa, T; Ota, M; Sato, T; Tsuji, M; Yamano, Y | 1 |
| Adam, HJ; Domalaon, R; Golden, AR; Idowu, T; Karlowsky, JA; Lagacé-Wiens, PRS; Lawrence, CK; Lynch Iii, JP; Noreddin, A; Schweizer, F; Walkty, AJ; Wiebe, K; Zelenitsky, S; Zhanel, GG; Zhanel, MA | 1 |
| Hsu, AJ; Tamma, PD | 1 |
| Bonomo, RA | 1 |
| Ariyasu, M; Echols, R; Nagata, TD | 1 |
| Adam, HJ; Baxter, M; Golden, AR; Karlowsky, JA; Lagacé-Wiens, P; Walkty, A; Zhanel, GG | 1 |
| Anacker, M; Castanheira, M; Johnson, JR; Johnston, BD; Porter, SB; Snippes Vagnone, P; Thuras, P; VonBank, B; Witwer, M | 1 |
| Barnini, S; Casella, C; Falcone, M; Forfori, F; Guarracino, F; Leonildi, A; Malacarne, P; Menichetti, F; Nicastro, M; Tiseo, G; Vecchione, A | 1 |
| Bassetti, M; Battaglini, D; Giacobbe, DR; Pelosi, P; Vena, A | 1 |
| Heil, EL; Tamma, PD | 1 |
| Ariyasu, M; Bassetti, M; Doi, Y; Echols, R; Ferrer, R; Lodise, TP; Matsunaga, Y; Naas, T; Nagata, TD; Niki, Y; Paterson, DL; Portsmouth, S; Torre-Cisneros, J; Toyoizumi, K; Wunderink, RG | 1 |
| Abbaszadeh, F; Baradaran, B; Dehghani, L; Hasani, A; Rezaee, MA; Samadi Kafil, H; Vahhabi, A | 1 |
| Choby, JE; Jacob, JT; Ozturk, T; Satola, SW; Weiss, DS | 1 |
| Boutin, S; Fiedler, MO; Hackert, T; Heeg, K; Klein, S; Kocer, K; Mehrabi, A; Mieth, M; Nurjadi, D; Richter, D; Rupp, C; Störzinger, D; Tan, B; Weigand, MA; Zimmermann, S | 1 |
| Alderete, JF; Cancio, LC; Carney, BW; Cindass, R; Markelz, AE; Rizzo, JA | 1 |
| Czech, M; Holubar, M; Ong'uti, S; Robilotti, E | 1 |
| Chakraborty, DS; Chatterjee, S; Choudhury, S; Lahiry, S | 1 |
| Caldwell, B; Hamprecht, A; Henriksen, AS; Longshaw, C; Thelen, P; Yamano, Y | 1 |
| Byrne, D; Lai, L; Rose, L | 1 |
| Doi, Y; Echols, R; Matsunaga, Y; Nordmann, P; Shields, RK; Takemura, M; Yamano, Y | 1 |
| Bush, K; Carpenter, J; Chu, TY; Divoky, C; Lee-Hsiao, C; Neidig, N; Sultana, R; Threatt, H; Zhang, Q | 1 |
| Barnini, S; Della Sala, L; Falcone, M; Farcomeni, A; Leonildi, A; Menichetti, F; Tiseo, G; Vecchione, A | 1 |
| Heil, EL; Hirsch, EB; Karaba, SM | 1 |
| Blandino-Ortiz, A; Montufar, J; Soriano, MC | 1 |
| Canton, R; Doi, Y; Simner, PJ | 1 |
| Bonnin, RA; Dortet, L; Emeraud, C; Jousset, AB; Naas, T | 1 |
| Actis, LA; Bonomo, RA; Escalante, J; Georgeos, N; Mezcord, V; Nishimura, B; Pasteran, F; Pimentel, C; Ramirez, MS; Rodriguez, C; Sieira, R; Subils, T; Tolmasky, ME; Tuttobene, MR | 1 |
| Birgy, A; Bonacorsi, S; Courroux, C; Danjean, M; Gits-Muselli, M; Hobson, CA; Monjault, A | 1 |
| Bergman, Y; Cosgrove, SE; Jacobs, EB; Lee, JH; Lewis, S; Simner, PJ; Tamma, PD | 1 |
| Abouelhassan, Y; Bourdages, G; Gutierrez, RL; Kufel, WD; Nicolau, DP; Perwez, T; Steele, JM | 1 |
| Brenner, T; Witzke, O | 1 |
| Mensa, J; Soriano, A | 1 |
| Cantón, R; Castillo-Polo, JA; Gijón Cordero, D; Ruiz-Garbajosa, P | 1 |
| Maseda, E; Suárez de la Rica, A | 1 |
| Gao, Z; Guan, J; He, Y; Li, Y; Ma, X; Ni, W; Wang, Y; Zhao, J | 1 |
| Dela-Pena, J; Gavaghan, V; Miller, JL | 1 |
| Bassetti, M; Castaldo, N; Giacobbe, DR; Grossi, PA; Peghin, M; Vena, A | 1 |
| Bonomo, RA; Corso, A; Mezcord, V; Pasteran, F; Ramirez, MS; Tolmasky, ME; Wong, O | 1 |
| Alalwan, B; Alghoribi, MF; Aljohani, S; Alreheli, A; Alzayer, M; Bosaeed, M; Doumith, M | 1 |
| Bassetti, M; Bini, L; Giacobbe, DR; Magnè, F; Vena, A | 1 |
| Bawankule, S; Joshi, P; Nabar, N; Singhal, T | 1 |
| Carmona, P; Córdoba-Fernández, M; de la Fuente, C; Domínguez, A; García, L; Guzmán-Puche, J; López-Viñau, T; Machuca, I; Martínez-Martínez, L; Merino, N; Robles, JC; Rodríguez, M; Torre-Cisneros, J; Vaquero, JM | 1 |
| Borrazzo, C; Bruni, A; Garofalo, E; Gullì, S; Lionello, R; Longhini, F; Marascio, N; Matera, G; Quirino, A; Romeo, F; Russo, A; Serapide, F; Serraino, R; Torti, C; Trecarichi, EM | 1 |
| Alonso-Garcia, I; Alvarez-Fraga, L; Arca-Suárez, J; Beceiro, A; Bou, G; González-Bello, C; Guijarro-Sánchez, P; Lasarte-Monterrubio, C; Lence, E; Maceiras, R; Martinez-Guitian, M; Outeda, M; Peña-Escolano, A; Vázquez-Ucha, JC | 1 |
| Coppi, M; Di Pilato, V; Montenora, I; Riccobono, E; Rossolini, GM; Salvetti, S | 1 |
| Dupont, H; Echols, R; Greenberg, DE; Kollef, M; Nicolau, DP; Viale, P; Yamano, Y | 1 |
| Buonomo, AR; Calò, F; Coppola, N; De Luca, I; Di Caprio, G; Durante-Mangoni, E; Gentile, I; Iuliano, P; Leone, S; Macera, M; Maggi, P; Massa, A; Monari, C; Numis, FG; Onorato, L; Pagliano, P | 1 |
| Aepfelbacher, M; Berinson, B; Berneking, L; Both, A; Brakert, L; Huang, J; Rohde, H; Wichmann, D; Wolschke, C | 1 |
| Actis, LA; Bonomo, RA; Escalante, J; Marin, I; Mezcord, V; Nishimura, B; Pasteran, F; Ramirez, MS; Rao, G; Sharma, R; Subils, T; Tolmasky, ME; Traglia, GM; Tuttobene, MR; Vallé, Q | 1 |
| Actis, LA; Bonomo, RA; Escalante, J; Mezcord, V; Nishimura, B; Pasteran, F; Ramirez, MS; Subils, T; Tolmasky, ME; Tuttobene, MR | 1 |
| Benzaarate, I; Bogaerts, P; Bourjilat, F; El Otmani, F; Huang, TD; Khazaz, A; Nayme, K; Timinouni, M | 1 |
| Barretti, P; Camargo, CH; Campos, KR; Cunha, MPV; de Souza, AR; Dos Santos, MB; Ferraro, PSP; Freire, MP; Sacchi, CT; Tiba-Casas, MR; Yamada, AY | 1 |
| Bartolini, A; Bartoloni, A; Bernardo, M; Bianco, V; Botta, A; Faragona, A; Giacometti, A; Giani, T; Graziani, L; Lagi, F; Morroni, G; Parrella, R; Piccica, M; Rossolini, GM; Spinicci, M; Tavio, M | 1 |
| Becker, K; Bohnert, JA; Bueter, A; Echelmeyer, T; Eger, E; Fickenscher, H; Guenther, S; Heiden, SE; Krumbholz, A; Maschkowitz, G; Nurjadi, D; Schaufler, K; Schwabe, M | 1 |
16 review(s) available for carbapenems and cefiderocol
| Article | Year |
|---|---|
Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli.
Topics: Animals; Anti-Bacterial Agents; Azabicyclo Compounds; beta-Lactamase Inhibitors; Carbapenems; Cefiderocol; Ceftazidime; Cephalosporins; Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug Combinations; Drug Resistance, Multiple, Bacterial; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Meropenem; Molecular Structure; Randomized Controlled Trials as Topic; Siderophores | 2019 |
Defining the Role of Novel β-Lactam Agents That Target Carbapenem-Resistant Gram-Negative Organisms.
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; Aztreonam; Boronic Acids; Carbapenems; Cefiderocol; Ceftazidime; Cephalosporins; Cilastatin, Imipenem Drug Combination; Drug Combinations; Drug Resistance, Multiple, Bacterial; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Heterocyclic Compounds, 1-Ring; Meropenem; Tazobactam | 2019 |
Pathogen-focused Clinical Development to Address Unmet Medical Need: Cefiderocol Targeting Carbapenem Resistance.
Topics: Anti-Bacterial Agents; Carbapenems; Cefiderocol; Cephalosporins; Clinical Trials as Topic; Drug Approval; Drug Resistance, Bacterial; Europe; Humans; United States; United States Food and Drug Administration | 2019 |
The role of new antimicrobials for Gram-negative infections in daily clinical practice.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Azabicyclo Compounds; beta-Lactams; Carbapenems; Cefiderocol; Ceftazidime; Cephalosporins; Drug Combinations; Drug Resistance, Bacterial; Gram-Negative Bacterial Infections; Humans; Imipenem; Microbial Sensitivity Tests; Polymyxins; Sisomicin; Tazobactam; Tetracyclines | 2020 |
A plethora of carbapenem resistance in
Topics: Acinetobacter baumannii; Anti-Bacterial Agents; Bacteriophages; beta-Lactamases; beta-Lactams; Carbapenems; Cefiderocol; Cephalosporins; Colistin; Drug Resistance, Multiple, Bacterial; Humans; Membrane Transport Proteins; Microbial Sensitivity Tests; Polymyxin B; Tetracyclines | 2021 |
Cefiderocol: A New Cephalosporin Stratagem Against Multidrug-Resistant Gram-Negative Bacteria.
Topics: Anti-Bacterial Agents; Carbapenems; Cefiderocol; Cephalosporins; Drug Resistance, Multiple, Bacterial; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Microbial Sensitivity Tests | 2022 |
Cefiderocol: A new Antimicrobial for Complicated Urinary Tract Infection (CUTI) Caused by Carbapenem-resistant Enterobacteriaceae (CRE).
Topics: Adult; Anti-Bacterial Agents; Carbapenem-Resistant Enterobacteriaceae; Carbapenems; Cefiderocol; Cephalosporins; Female; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Male; Siderophores; Urinary Tract Infections | 2022 |
Cefiderocol.
Topics: Anti-Bacterial Agents; Carbapenems; Cefiderocol; Cephalosporins; Gram-Negative Bacteria; Humans | 2022 |
Treatment of carbapenem-resistant
Topics: Anti-Bacterial Agents; beta-Lactamase Inhibitors; Carbapenems; Cefiderocol; Cephalosporins; Humans; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections | 2022 |
[Clinical experience using cefiderocol].
Topics: Adult; Anti-Bacterial Agents; Carbapenems; Cefiderocol; Cephalosporins; Humans; Monobactams | 2023 |
Mechanism of action of cefiderocol.
Topics: Animals; Anti-Bacterial Agents; beta-Lactamase Inhibitors; beta-Lactamases; Carbapenems; Cattle; Cefepime; Cefiderocol; Ceftazidime; Cephalosporins; Gram-Negative Bacteria; Iron; Quinolones; Serine; Tetracyclines | 2022 |
Antibacterial spectrum of cefiderocol.
Topics: Anti-Bacterial Agents; beta-Lactamases; Carbapenems; Catechols; Cefiderocol; Cephalosporins; Drug Resistance, Multiple, Bacterial; Humans; Iron; Microbial Sensitivity Tests; Porins; Pseudomonas aeruginosa; Siderophores | 2022 |
The role of cefiderocol in clinical practice.
Topics: Anti-Bacterial Agents; beta-Lactamases; Carbapenems; Cefepime; Cefiderocol; Ceftazidime; Cephalosporins; Drug Resistance, Multiple, Bacterial; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Microbial Sensitivity Tests; Pseudomonas aeruginosa | 2022 |
Clinical evidence supporting cefiderol for serious Acinetobacter baumannii infections.
Topics: Acinetobacter baumannii; Anti-Bacterial Agents; Carbapenems; Cefiderocol; Cephalosporins; Drug Resistance, Multiple, Bacterial; Humans; Microbial Sensitivity Tests | 2022 |
New antibiotics for Gram-negative pneumonia.
Topics: Anti-Bacterial Agents; Carbapenems; Cefiderocol; Drug Combinations; Drug Resistance, Multiple, Bacterial; Gram-Negative Bacteria; Humans; Imipenem; Pneumonia, Bacterial | 2022 |
Prospective role of cefiderocol in the management of carbapenem-resistant Acinetobacter baumannii infections: Review of the evidence.
Topics: Acinetobacter baumannii; Anti-Bacterial Agents; beta-Lactamases; Carbapenems; Cefiderocol; Cephalosporins; Drug Resistance, Multiple, Bacterial; Gram-Negative Bacteria; Humans; Microbial Sensitivity Tests; Prospective Studies; Randomized Controlled Trials as Topic | 2023 |
2 trial(s) available for carbapenems and cefiderocol
| Article | Year |
|---|---|
Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Bacteremia; Carbapenems; Cefiderocol; Cephalosporins; Drug Resistance, Bacterial; Female; Gram-Negative Bacterial Infections; Humans; Male; Middle Aged; Pneumonia, Bacterial; Sepsis; Urinary Tract Infections; Young Adult | 2021 |
Mechanisms of Reduced Susceptibility to Cefiderocol Among Isolates from the CREDIBLE-CR and APEKS-NP Clinical Trials.
Topics: Anti-Bacterial Agents; Carbapenems; Cefiderocol; Cephalosporins; Escherichia coli; Humans; Microbial Sensitivity Tests | 2022 |
38 other study(ies) available for carbapenems and cefiderocol
| Article | Year |
|---|---|
In Vitro Antimicrobial Activity of a Siderophore Cephalosporin, S-649266, against Enterobacteriaceae Clinical Isolates, Including Carbapenem-Resistant Strains.
Topics: Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; Carbapenems; Cefiderocol; Cephalosporins; Enterobacteriaceae; Escherichia coli Proteins; Humans; Microbial Sensitivity Tests; Siderophores | 2016 |
Activity of cefiderocol (S-649266) against carbapenem-resistant Gram-negative bacteria collected from inpatients in Greek hospitals.
Topics: Acinetobacter baumannii; Anti-Bacterial Agents; Bacterial Proteins; beta-Lactam Resistance; beta-Lactamases; Carbapenems; Cefepime; Cefiderocol; Ceftazidime; Cephalosporins; Colistin; Drug Resistance, Multiple, Bacterial; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Greece; Humans; Inpatients; Klebsiella pneumoniae; Meropenem; Microbial Sensitivity Tests; Minocycline; Pseudomonas aeruginosa; Thienamycins; Tigecycline | 2017 |
Stability and low induction propensity of cefiderocol against chromosomal AmpC β-lactamases of Pseudomonas aeruginosa and Enterobacter cloacae.
Topics: Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; Carbapenems; Cefiderocol; Cephalosporins; Chromosomes, Bacterial; Drug Resistance, Multiple, Bacterial; Enterobacter cloacae; Imipenem; Microbial Sensitivity Tests; Pseudomonas aeruginosa | 2018 |
Cefiderocol: A Novel Siderophore Cephalosporin Defeating Carbapenem-resistant Pathogens.
Topics: Anti-Bacterial Agents; Carbapenems; Cefiderocol; Cephalosporins; Drug Resistance, Bacterial; Humans; Siderophores | 2019 |
In Vitro Activity of Cefiderocol, a Novel Siderophore Cephalosporin, against Gram-Negative Bacilli Isolated from Patients in Canadian Intensive Care Units.
Topics: Acinetobacter baumannii; Anti-Bacterial Agents; Canada; Carbapenems; Cefiderocol; Cephalosporins; Drug Resistance, Multiple, Bacterial; Enterobacteriaceae; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Intensive Care Units; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Siderophores; Stenotrophomonas maltophilia | 2020 |
Activity of Cefiderocol, Ceftazidime-Avibactam, and Eravacycline against Carbapenem-Resistant Escherichia coli Isolates from the United States and International Sites in Relation to Clonal Background, Resistance Genes, Coresistance, and Region.
Topics: Anti-Bacterial Agents; Asia; Azabicyclo Compounds; beta-Lactamases; Carbapenems; Cefiderocol; Ceftazidime; Cephalosporins; Drug Combinations; Escherichia coli; Europe; Latin America; Microbial Sensitivity Tests; Phylogeny; Tetracyclines; United States | 2020 |
Cefiderocol as Rescue Therapy for Acinetobacter baumannii and Other Carbapenem-resistant Gram-negative Infections in Intensive Care Unit Patients.
Topics: Acinetobacter baumannii; Anti-Bacterial Agents; beta-Lactamases; Carbapenems; Cefiderocol; Cephalosporins; Humans; Intensive Care Units; Microbial Sensitivity Tests; Prospective Studies | 2021 |
Cefiderocol: the Trojan horse has arrived but will Troy fall?
Topics: Bacteria; Carbapenems; Cefiderocol; Cephalosporins; Gram-Negative Bacteria | 2021 |
Widespread cefiderocol heteroresistance in carbapenem-resistant Gram-negative pathogens.
Topics: Carbapenems; Cefiderocol; Cephalosporins; Gram-Negative Bacteria; Humans | 2021 |
Rapid Development of Cefiderocol Resistance in Carbapenem-resistant Enterobacter cloacae During Therapy Is Associated With Heterogeneous Mutations in the Catecholate Siderophore Receptor cirA.
Topics: Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; Carbapenems; Cefiderocol; Cephalosporins; Enterobacter cloacae; Humans; Microbial Sensitivity Tests; Mutation; Siderophores | 2022 |
Carbapenem-Resistant Enterobacterales Infection After Massive Blast Injury: Use of Cefiderocol Based Combination Therapy.
Topics: Anti-Bacterial Agents; Blast Injuries; Carbapenems; Cefiderocol; Cephalosporins; Escherichia coli; Humans; Male; Microbial Sensitivity Tests | 2021 |
In vitro activity of cefiderocol against Gram-negative bacterial pathogens in Germany.
Topics: Anti-Bacterial Agents; Carbapenems; Cefiderocol; Ceftazidime; Cephalosporins; Colistin; Drug Resistance, Multiple, Bacterial; Gram-Negative Bacteria; Humans; Tazobactam | 2022 |
Successful prolonged treatment of a carbapenem-resistant Acinetobacter baumannii hip infection with cefiderocol: A case report.
Topics: Acinetobacter baumannii; Anti-Bacterial Agents; Carbapenems; Cefiderocol; Cephalosporins; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Osteomyelitis | 2022 |
In vitro antibacterial activity of cefiderocol against recent multidrug-resistant carbapenem-nonsusceptible Enterobacterales isolates.
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; beta-Lactamases; Carbapenems; Cefiderocol; Cephalosporins; Drug Combinations; Humans; Meropenem; Microbial Sensitivity Tests | 2022 |
Cefiderocol- Compared to Colistin-Based Regimens for the Treatment of Severe Infections Caused by Carbapenem-Resistant Acinetobacter baumannii.
Topics: Acinetobacter baumannii; Anti-Bacterial Agents; Carbapenems; Cefiderocol; Cephalosporins; Colistin; Humans; Pneumonia, Ventilator-Associated; Retrospective Studies; Sepsis | 2022 |
In a Pinch: Cefiderocol for CRAB Infections.
Topics: Acinetobacter baumannii; Acinetobacter Infections; Anti-Bacterial Agents; Carbapenems; Cefiderocol; Cephalosporins; Humans; Microbial Sensitivity Tests; Retrospective Studies | 2022 |
Comparison of disk diffusion, MIC test strip and broth microdilution methods for cefiderocol susceptibility testing on carbapenem-resistant enterobacterales.
Topics: Anti-Bacterial Agents; Carbapenems; Cefiderocol; Cephalosporins; Humans; Microbial Sensitivity Tests; Reproducibility of Results | 2022 |
Acinetobacter baumannii response to cefiderocol challenge in human urine.
Topics: Acinetobacter baumannii; Albumins; Anti-Bacterial Agents; beta-Lactamases; Carbapenems; Cefiderocol; Cephalosporins; Humans; Iron; Microbial Sensitivity Tests; Siderophores | 2022 |
Evaluation of the inoculum effect of new antibiotics against carbapenem-resistant enterobacterales.
Topics: Anti-Bacterial Agents; beta-Lactamase Inhibitors; Carbapenems; Cefiderocol; Humans; Imipenem; Meropenem; Tazobactam | 2022 |
Comparing the activity of novel antibiotic agents against carbapenem-resistant Enterobacterales clinical isolates.
Topics: Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; Carbapenems; Cefiderocol; Ceftazidime; Drug Combinations; Humans; Klebsiella pneumoniae; Meropenem; Microbial Sensitivity Tests | 2023 |
Plasma and cerebrospinal fluid concentrations of cefiderocol during successful treatment of carbapenem-resistant Acinetobacter baumannii meningitis.
Topics: Acinetobacter baumannii; Anti-Bacterial Agents; Carbapenems; Cefiderocol; Cephalosporins; Female; Gentamicins; Humans; Meningitis; Microbial Sensitivity Tests; Middle Aged | 2022 |
In vitro and in vivo efficacy of cefiderocol plus tigecycline, colistin, or meropenem against carbapenem-resistant Acinetobacter baumannii.
Topics: Acinetobacter baumannii; Acinetobacter Infections; Anti-Bacterial Agents; Carbapenems; Cefiderocol; Colistin; Drug Resistance, Multiple, Bacterial; Drug Synergism; Humans; Meropenem; Microbial Sensitivity Tests; Tigecycline | 2022 |
Case series of cefiderocol for salvage therapy in carbapenem-resistant Gram-negative infections.
Topics: Adult; Anti-Bacterial Agents; Carbapenems; Cefiderocol; Cephalosporins; Drug Resistance, Multiple, Bacterial; Gram-Negative Bacteria; Humans; Microbial Sensitivity Tests; Retrospective Studies; Salvage Therapy | 2023 |
Role of β-lactamase inhibitors on cefiderocol activity against carbapenem-resistant Acinetobacter species.
Topics: Acinetobacter; Acinetobacter baumannii; Anti-Bacterial Agents; beta-Lactamase Inhibitors; beta-Lactamases; Carbapenems; Cefiderocol; Cephalosporins; Microbial Sensitivity Tests | 2023 |
In vitro activity of cefiderocol against clinically important carbapenem non-susceptible Gram-negative bacteria from Saudi Arabia.
Topics: Anti-Bacterial Agents; Carbapenems; Cefiderocol; Cephalosporins; Escherichia coli; Gram-Negative Bacteria; Klebsiella pneumoniae; Pseudomonas aeruginosa; Saudi Arabia | 2023 |
Cefiderocol as Salvage Therapy for Carbapenem-Resistant Klebsiella pneumoniae Sepsis in an Extremely Preterm Neonate.
Topics: Anti-Bacterial Agents; Carbapenem-Resistant Enterobacteriaceae; Carbapenems; Cefiderocol; Humans; Infant, Extremely Premature; Infant, Newborn; Klebsiella pneumoniae; Microbial Sensitivity Tests; Salvage Therapy; Sepsis | 2023 |
Real-life use of cefiderocol for salvage therapy of severe infections due to carbapenem-resistant Gram-negative bacteria.
Topics: Anti-Bacterial Agents; Carbapenems; Cefiderocol; Cephalosporins; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Retrospective Studies; Salvage Therapy | 2023 |
Efficacy of cefiderocol- vs colistin-containing regimen for treatment of bacteraemic ventilator-associated pneumonia caused by carbapenem-resistant Acinetobacter baumannii in patients with COVID-19.
Topics: Acinetobacter baumannii; Anti-Bacterial Agents; Bacteremia; Carbapenems; Cefiderocol; Colistin; COVID-19; Fosfomycin; Humans; Pneumonia, Ventilator-Associated | 2023 |
Antimicrobial Activity of Cefiderocol against the Carbapenemase-Producing Enterobacter cloacae Complex and Characterization of Reduced Susceptibility Associated with Metallo-β-Lactamase VIM-1.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; beta-Lactamases; Carbapenem-Resistant Enterobacteriaceae; Carbapenems; Cefiderocol; Cephalosporins; Enterobacter cloacae; Microbial Sensitivity Tests; Siderophores | 2023 |
Citrobacter freundii resistant to novel β-lactamase inhibitor combinations and cefiderocol, co-producing class A, B and D carbapenemases encoded by transferable plasmids.
Topics: Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamase Inhibitors; beta-Lactamases; Carbapenems; Cefiderocol; Citrobacter freundii; Drug Combinations; Humans; Microbial Sensitivity Tests; Plasmids | 2023 |
Outcome of patients with carbapenem-resistant Acinetobacter baumannii infections treated with cefiderocol: A multicenter observational study.
Topics: Acinetobacter baumannii; Acinetobacter Infections; Aged; Anti-Bacterial Agents; Carbapenems; Cefiderocol; Female; Humans; Male; Prospective Studies; Retrospective Studies | 2023 |
Rapid development of cefiderocol resistance in a carbapenem-resistant Pseudomonas aeruginosa isolate associated with mutations in the pyoverdine biosynthesis pathway.
Topics: Anti-Bacterial Agents; Carbapenems; Cefiderocol; Humans; Iron; Mutation; Pseudomonas aeruginosa | 2023 |
Induced Heteroresistance in Carbapenem-Resistant
Topics: Acinetobacter baumannii; Acinetobacter Infections; Anti-Bacterial Agents; beta-Lactamases; Carbapenems; Cefiderocol; Humans; Iron; Microbial Sensitivity Tests | 2023 |
Human serum albumin-induced modification of Ton-B-dependent receptor expression in cefiderocol-exposed carbapenem-resistant Acinetobacter baumannii.
Topics: Acinetobacter baumannii; Anti-Bacterial Agents; Carbapenems; Cefiderocol; Cephalosporins; Humans; Microbial Sensitivity Tests | 2023 |
Detection of Carbapenemase Encoding Gene and Resistance to Cefiderocol in Hospital and Community eXtensive Drug Resistance and Carbapenem-Resistant
Topics: Anti-Bacterial Agents; beta-Lactamases; Carbapenems; Cefiderocol; Drug Resistance; Hospitals; Microbial Sensitivity Tests; Morocco; Pseudomonas aeruginosa | 2023 |
Genomic analysis and antimicrobial activity of β-lactam/β-lactamase inhibitors and other agents against KPC-producing Klebsiella pneumoniae clinical isolates from Brazilian hospitals.
Topics: beta-Lactamase Inhibitors; Brazil; Carbapenems; Cefiderocol; Genomics; Klebsiella pneumoniae; Lactams; Meropenem | 2023 |
Cefiderocol use for the treatment of infections by carbapenem-resistant Gram-negative bacteria: an Italian multicentre real-life experience.
Topics: Acinetobacter Infections; Aged; Anti-Bacterial Agents; Carbapenems; Cefiderocol; Cephalosporins; Female; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Male; Retrospective Studies | 2023 |
Convergent
Topics: Anti-Bacterial Agents; beta-Lactamases; Carbapenems; Cefiderocol; Cephalosporins; Disease Outbreaks; Klebsiella pneumoniae; Multilocus Sequence Typing | 2023 |